FDA says Ozempic, Wegovy are not in short supply anymore, which could impact prices
The U.S. Food and Drug Administration said Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply. CBS News New York reporter Ali Bauman reports on whether the supply change could lead to consumers paying more.
Taking tiny doses of GLP-1 medication has been touted for weight management, perimenopause symptoms, even longevity. But is ...
Microdosing glp-1 is gaining traction, but is it safe? Experts warn about compounded semaglutide, reduced efficacy, and ...
The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive ...
The rise in GLP-1 drugs is undeniable. Morgan Stanley projects that by 2035, 24 million Americans, or 7% of the population, ...
A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and ...
Conagra and General Mills are among the food companies offering special options for people on GLP-1 drugs, but the products ...
Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback